glp-1 agonists blindness risk The Effect of Semaglutide and RAs on of Nonarteritic Anterior Ischemic Optic Neuropathy GLP-1/GIP Receptor Agonists and Diabetic

Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study

95% CI, 0.23-0.38).2 Additionally, teclistamab reduced the risk of death by 40% compared with SOC treatment (HR, 0.60

Receiver operating characteristic (ROC) analysis found 7.5 days of withholding the medication as cutoff for increased prevalence of high RGC in patients taking GLP-1 injections

In 2020 the first small-molecule structure (Zhao et al) revealed a druggable transmembrane sub-pocket distinct from the peptide-binding interface

Large employer health benefit plans increasingly include GLP-1 medications in formularies, though typically with prior authorization requirements and step therapy protocols

Kroemer, G., Maier, A